Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 303

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 303
---
:-----------|--------------:|:--|:----|:-------------|-------------:|:--|
|                                                                      |     | -Successor |               |   |     | -Predecessor |              |   |
| Right-of-use assets, net                                             |     | $          |     1,652,614 |   |     | $            |    2,189,565 |   |
| Operating lease liabilities, current                                 |     | $          |       931,023 |   |     | $            |      769,092 |   |
| Operating lease liabilities, non-current                             |     |            |       771,525 |   |     |              |    1,575,499 |   |
| Total operating lease liabilities                                    |     | $          |     1,702,548 |   |     | $            |    2,344,591 |   |
| Weighted-average remaining lease term of operating leases (in years) |     |            |          2.00 |   |     |              |         2.75 |   |
| Weighted-average discount rate for operating leases                  |     |            |          9.60 | % |     |              |         9.60 | % |

F-14

The following table reconciles the undiscounted
future minimum lease payments (displayed by year and in the aggregate) under non-cancelable operating leases with terms of more than to the total operating lease liabilities recognized on the Company’s condensed consolidated balance sheets as of September
30, 2024:

| Remainder of 2024       |     | $ |   168,133 |   |
| 2025                    |     |   |   990,055 |   |
| 2026                    |     |   |   726,394 |   |
| Total lease payments    |     |   | 1,884,582 |   |
| Less: imputed interest  |     |   |  (182,034 | ) |
| Total lease liabilities |     | $ | 1,702,548 |   |

NOTE 7 – STOCKHOLDERS’ DEFICIT Successor Series A Convertible Preferred Stock The Company designated 12,580shares of its authorized preferred stock as the Series A Preferred Stock and the rights, preferences and privileges of the Series A Preferred Stock are summarized below. Each share of Series A Preferred Stock has a stated value of $